Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
Moodys
Medtronic
AstraZeneca
Mallinckrodt
Baxter

Last Updated: January 26, 2022

DrugPatentWatch Database Preview

Claims for Patent: 10,196,696

➤ Subscribe for complete access

« Back to Dashboard

Summary for Patent: 10,196,696
Title:RNA-biomarkers for diagnosis of prostate cancer
Abstract: The invention relates to the identification and selection of differentially expressed transcripts (biomarker) in tumour cells. Specific determination of the level of these biomarkers can be used for screening and diagnosis of prostate cancer. Clinical application of assays based on these biomarker help reduce the high number of false positives of current standard screening assays.
Inventor(s): Horn; Friedemann (Leipzig, DE), Hackermuller; Jorg (Leipzig, DE), Christ; Sabina (Leipzig, DE), Reiche; Kristin (Leipzig, DE), Wirth; Manfred (Leipzig, DE), Frohner; Michael (Leipzig, DE), Fussel; Susanne (Leipzig, DE)
Assignee: FRAUNHOFER-GESELLSCHAFT ZUR FORDERUNG DER ANGEWAND (Munchen, DE)
Application Number:15/100,949
Patent Claims:1. A method for the diagnosis and treatment of prostate cancer comprising the steps of a) detecting the expression level of a nucleic acid according to SEQ ID NO: 12 in a sample from a patient, wherein the detection of the expression level is performed by next generation sequencing, b) diagnosing the subject as prostate cancer positive when the expression level difference between said patient sample and a control sample is at least 2 fold .+-.20%, and c) treating the prostate cancer positive subject with one or more prostate cancer therapeutic agents selected from the group consisting of Docetaxel, Cabazitaxel, Mitoxan-trone, Estramustine, Doxorubicin, etoposide, Vinblastine, Paclitaxel, Carboplatin, Abiraterone acetate, Bicalutamide, Casodes, Degarelix, Enzalutamide, Goserelin acetate, Leuprolide acetate, Prednisone, Sipuleucel-T, Radium 223 dichloride and Vinorelbine.

2. The method according to claim 1, wherein the sample is selected from the group comprising prostate tissue, biopsy material, lymph nodes, urine, ejaculate, blood, blood serum, blood plasma, circulating tumor cells in blood or lymph, any tissue derived or obtainable from a patient suspected of containing metastases as well as any biological source that may contain prostate tumor cells or parts thereof, wherein said parts comprise vesicles like exosomes, micro vesicles, and others as well as free or protein-bound RNA molecules derived from prostate tumor cells.

3. The method according to claim 1, wherein the sample is a urine sample.

4. The method according to claim 1, wherein the next generation sequencing is performed by measuring the fluorescence of a labelled primer, labelled probe or a fluorescent detection agent.

5. The method according to claim 1, wherein the next generation sequencing is performed by qRT-PCR.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
Moodys
Dow
McKesson
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.